Keyphrases
Specific Targeting
100%
Plasma Kallikrein
100%
Hereditary Angioedema
100%
C1 Inhibitor
81%
Bradykinin
18%
Angioedema
18%
Kallikrein Inhibitor
18%
Airway
9%
Receptor Activation
9%
New Therapies
9%
Life-threatening
9%
Daily Activities
9%
Smooth muscle Contraction
9%
Subcutaneous Injection
9%
Intravenous Injection
9%
Abdomen
9%
Genetic Disease
9%
Oral Formulation
9%
Vasodilation
9%
On Demand
9%
Genetic mutation
9%
Genitourinary System
9%
Evolving Landscape
9%
Submucosal
9%
Angioedema Attack
9%
Inherited mutation
9%
Spontaneous mutation
9%
Emerging Therapies
9%
Historical Review
9%
Increased Vascular Permeability
9%
Fluid Extravasation
9%
Bradykinin Receptor
9%
Kallikrein-kinin
9%
SERPING1 Gene
9%
Medicine and Dentistry
Hereditary Angioedema
100%
Plasma Kallikrein
100%
Angioedema
30%
Bradykinin
20%
Kallikrein Inhibitor
20%
Drug Therapy
10%
Genetic Disorder
10%
Smooth Muscle Contraction
10%
Subcutaneous Injection
10%
Gene Mutation
10%
Vasodilatation
10%
Extravasation
10%
Genitourinary System
10%
Kallikrein
10%
Spontaneous Mutation
10%
Blood Vessel Permeability
10%
Kinin
10%
Bradykinin Receptor
10%
Pharmacology, Toxicology and Pharmaceutical Science
Plasma Kallikrein
100%
Angioneurotic Edema
100%
Bradykinin
15%
Kallikrein Inhibitor
15%
Genetic Disorder
7%
Extravasation
7%
Kinin
7%
Kallikrein
7%
Bradykinin Receptor
7%